kabutan

Cyfuse Biomedical K.K.(4892) Summary

4892
TSE Growth
Cyfuse Biomedical K.K.
578
JPY
-5
(-0.86%)
Dec 5, 2:09 pm JST
3.73
USD
Dec 5, 12:09 am EST
Result
PTS
outside of trading hours
579.9
Dec 5, 1:51 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.01
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
582 JPY 3.75 USD
Previous Close Dec 4
583 JPY 3.75 USD
High Dec 5, 9:05 am
587 JPY 3.78 USD
Low Dec 5, 12:41 pm
577 JPY 3.71 USD
Volume
26,900
Trading Value
0.02B JPY 0.10M USD
VWAP
581.41 JPY 3.75 USD
Minimum Trading Value
57,800 JPY 373 USD
Market Cap
5.55B JPY 0.04B USD
Number of Trades
94
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Slightly High
1-Year Average
747
1-Year High Feb 13, 2025
14,682
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 1,028,900
Nov 21, 2025 0 1,048,500
Nov 14, 2025 700 1,102,600 1575.14
Nov 7, 2025 0 1,119,000
Oct 31, 2025 0 1,124,800
Company Profile
Cyfuse Biomedical K.K. engages in the development, manufacturing, and sales of regenerative medicine products using bio 3D printers.
Sector
Pharmaceuticals
Cyfuse Biomedical K.K. primarily focuses on the development, manufacturing, and sales of regenerative medicine products using bio 3D printers, while expanding its multifaceted business across three domains: regenerative medicine, drug discovery support, and devices. In the regenerative medicine field, the company develops new regenerative medicine products by creating three-dimensional tissues and organs made solely from cells, advancing multiple pipelines such as peripheral nerve regeneration and bone and cartilage regeneration. In the drug discovery support area, Cyfuse offers contract research services for cell products and develops and sells new 3D cell products like organ models. In the device domain, the company develops and sells bio 3D printers, applies technologies necessary for cell product development, and creates new technologies. Through its proprietary core technology and strategic partnerships, Cyfuse Biomedical K.K. aims to realize innovative regenerative medicine products.